Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECT-001-expanded cord blood
- Development stage
- Unknown
- Lead developer
- ExCellThera
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ECT-001-expanded cord blood is an ex vivo expanded allogeneic cell therapy derived from a single umbilical cord blood (UCB) unit. The expansion process utilizes UM171, a small molecule agonist that promotes the self-renewal of hematopoietic stem cells (HSCs) while preventing their differentiation. The final product consists of UM171-expanded CD34+ hematopoietic stem and progenitor cells (HSPCs) combined with the unexpanded CD34- fraction from the same donor unit. Administered intravenously, ECT-001 is designed to provide rapid and robust engraftment in patients undergoing hematopoietic stem cell transplantation (HCT), particularly those with high-risk myeloid malignancies who lack a suitable matched donor. It has received conditional marketing authorization in the European Union under the brand name Zemcelpro for certain hematologic conditions.
- Brand names
- Zemcelpro
- Other names
- UM171-expanded cord bloodUM-171-expanded cord bloodUM 171-expanded cord bloodexpanded umbilical cord blood
02
Targets
CD34 (CD34 antigen)
Beyond the preview
Go deeper on ECT-001-expanded cord blood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECT-001-expanded cord blood.